Pomerantz LLP is investigating claims on behalf of investors of Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL). Such investors are ...

News is breaking today that Replimune Group, Inc.'s (REPL) Biologics License Application ("BLA") requesting approval for its drug candidate RP1 (vusolimogene oderparepvec) in the indication of anti-PD ...

Replimune (REPL) has announced that it has no other option but to reduce its workforce and scale back U.S. manufacturing operations after the FDA on Friday declined to approve its lead asset, RP1, ...

Troy Segal is an editor and writer. She has 20+ years of experience covering personal finance, wealth management, and business news. Andy Smith is a Certified Financial Planner (CFP®), licensed ...

Barclays, Experian and UBS join the FCA’s live AI testing initiative, exploring cutting-edge technologies like agentic AI and SLMs to ensure safe, responsible innovation in UK financial markets ...

NIST announces big changes to the way it categorises and manages CVEs, which are set to have a big impact on how organisations manage patching and remediation Continue Reading ...

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Mike Miliard is Executive Editor of Healthcare IT News. He focuses on topics such as interoperability, cybersecurity, artificial intelligence, analytics, population health and patient experience and ...